Clinical trial
Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With…
NCT00142415 · Ludwig Institute for Cancer Research, Other · Completed
Key facts
| NCT number | NCT00142415 |
|---|---|
| Title | Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer |
| Official title | Phase I/II Study of Increasing Doses of Lutetium-177 Labeled Chimeric Monoclonal Antibody cG250 (177^Lu-DOTA-cG250) in Patients With Advanced Renal Cancer |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Collaborators | Radboud University Medical Center |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | 111-In-DOTA-cG250, 177-Lu-DOTA-cG250 |
| Enrollment | 26 |
| Start date | Feb 1, 2005 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Sep 2, 2005 |
| Last update posted | Oct 28, 2022 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: